Key result
Dipyridamole significantly reduced plasma vWf levels in both healthy volunteers (-10.0%) and stroke patients (-10.11%) (p<0.05), demonstrating non-platelet-related effects of antiplatelet agents.
Why the study?
Do aspirin, clopidogrel, and dipyridamole, alone or in combination, improve soluble markers of vascular function in healthy volunteers and patients with prior ischemic stroke?
Population
n=22 (11 healthy subjects and 11 patients with previous ischaemic stroke)
Comparison
Aspirin, clopidogrel, and dipyridamole… vs Other antiplatelet regimens (crossover design)
Design
RCT, random order, measured blinded to treatment
Follow-up
2 weeks per treatment period
Authors
Loading...
May support non-platelet effects of dipyridamole on vWf; hypothesis-generating and should not yet change practice.
RCT (n=22)
Blinded
Random order
Do aspirin, clopidogrel, and dipyridamole, alone or in combination, improve soluble markers of vascular function in healthy volunteers and patients with prior ischemic stroke?
p-value: p=< 0.05
Zhao et al. (2006) conducted an RCT in Previous ischaemic stroke and healthy volunteers (n=22). Aspirin, clopidogrel, and dipyridamole (singly and in combination) vs. Mono, dual, and triple therapy compared to each other was evaluated on Plasma von Willebrand factor (vWf) levels (p=< 0.05). Dipyridamole significantly reduced plasma vWf levels in both healthy volunteers (-10.0%) and stroke patients (-10.11%) (p<0.05), demonstrating non-platelet-related effects of antiplatelet agents.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: